The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection
© 2020 British HIV Association..
OBJECTIVES: To assess the effect of protease inhibitor (PI)-based dual therapy on CD4/CD8 ratio during the first year of therapy in antiretroviral therapy (ART)-naïve patients using data from randomized controlled clinical trials.
METHODS: We pooled data from the GARDEL and ANDES studies, both randomized controlled clinical trials that recruited ART-naïve people living with HIV and randomly assigned them to receive PI-based dual therapy (DT) or triple therapy (TT) aiming to compare viral efficacy. We compared median CD4/CD8 ratios and the proportion of patients with CD4/CD8 ratio > 1 at 48 weeks after ART initiation in both treatment arms using the Mann-Whitney U-test and the χ2 test. We performed subgroup analysis for patients > 50 years old, with baseline CD4 counts ≤ 200 cells/μL, viral load > 100 000 HIV RNA copies/mL, and ritonavir-boosted lopinavir-based therapy.
RESULTS: We analysed data from 571 patients: 292 on DT and 279 on TT. No differences were observed in CD4/CD8 ratio (0.632 vs. 0.617, P = 0.729) or in the proportion of patients with CD4/CD8 ratio > 1 (17.9% vs. 19.3%, P = 0.678) 48 weeks after ART initiation. Subgroup analysis showed no further differences.
CONCLUSION: The impact of PI-based DT regimens on the CD4/CD8 ratio during the first year of treatment for ART-naïve patients is similar to that of TT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
HIV medicine - 22(2021), 4 vom: 01. Apr., Seite 254-261 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Figueroa, M I [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 14.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/hiv.13008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319014703 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319014703 | ||
| 003 | DE-627 | ||
| 005 | 20231225170548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hiv.13008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319014703 | ||
| 035 | |a (NLM)33336523 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Figueroa, M I |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 14.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 British HIV Association. | ||
| 520 | |a OBJECTIVES: To assess the effect of protease inhibitor (PI)-based dual therapy on CD4/CD8 ratio during the first year of therapy in antiretroviral therapy (ART)-naïve patients using data from randomized controlled clinical trials | ||
| 520 | |a METHODS: We pooled data from the GARDEL and ANDES studies, both randomized controlled clinical trials that recruited ART-naïve people living with HIV and randomly assigned them to receive PI-based dual therapy (DT) or triple therapy (TT) aiming to compare viral efficacy. We compared median CD4/CD8 ratios and the proportion of patients with CD4/CD8 ratio > 1 at 48 weeks after ART initiation in both treatment arms using the Mann-Whitney U-test and the χ2 test. We performed subgroup analysis for patients > 50 years old, with baseline CD4 counts ≤ 200 cells/μL, viral load > 100 000 HIV RNA copies/mL, and ritonavir-boosted lopinavir-based therapy | ||
| 520 | |a RESULTS: We analysed data from 571 patients: 292 on DT and 279 on TT. No differences were observed in CD4/CD8 ratio (0.632 vs. 0.617, P = 0.729) or in the proportion of patients with CD4/CD8 ratio > 1 (17.9% vs. 19.3%, P = 0.678) 48 weeks after ART initiation. Subgroup analysis showed no further differences | ||
| 520 | |a CONCLUSION: The impact of PI-based DT regimens on the CD4/CD8 ratio during the first year of treatment for ART-naïve patients is similar to that of TT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CD4-CD8 ratio | |
| 650 | 4 | |a Darunavir | |
| 650 | 4 | |a Lamivudine | |
| 650 | 4 | |a Lopinavir | |
| 650 | 4 | |a dual therapy | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Camiro-Zuñiga, A |e verfasserin |4 aut | |
| 700 | 1 | |a Belaunzaran-Zamudio, P F |e verfasserin |4 aut | |
| 700 | 1 | |a Sierra Madero, J |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade Villanueva, J |e verfasserin |4 aut | |
| 700 | 1 | |a Arribas, J R |e verfasserin |4 aut | |
| 700 | 1 | |a Lama, J R |e verfasserin |4 aut | |
| 700 | 1 | |a Cecchini, D M |e verfasserin |4 aut | |
| 700 | 1 | |a Lopardo, G |e verfasserin |4 aut | |
| 700 | 1 | |a Crabtree-Ramírez, B |e verfasserin |4 aut | |
| 700 | 1 | |a Gun, A |e verfasserin |4 aut | |
| 700 | 1 | |a Patterson, P |e verfasserin |4 aut | |
| 700 | 1 | |a Fink, V I |e verfasserin |4 aut | |
| 700 | 1 | |a Sued, O G |e verfasserin |4 aut | |
| 700 | 1 | |a Cahn, P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV medicine |d 1999 |g 22(2021), 4 vom: 01. Apr., Seite 254-261 |w (DE-627)NLM116282541 |x 1468-1293 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:4 |g day:01 |g month:04 |g pages:254-261 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.13008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 4 |b 01 |c 04 |h 254-261 | ||